GenoMe

GenoMe (genometest.eu) will navigate you in complex space of DNA analysis and Virtual Doctor give you proposal of diagnostics testing. Multilanguage (ENG,DE,FR,POL) web-based service that helps you read and understand your DNA and your future offspring. After providing a saliva sample using an at-home kit, you can use our service to shed new light on your inherited conditions and traits. Combine your result with your partner to show genetic background of your future offspring and learn what your children can inherit. You can also find your genetically matched partner on our portal Genmatch.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MONSANTO AND DOW AGROSCIENCES ANNOUNCE GLOBAL LICENSING AGREEMENT ON EXZACT PRECISION TECHNOLOGY GENOME-EDITING PLATFORM

Dow AgroSciences | October 03, 2016

news image

Monsanto Company (NYSE: MON) and Dow AgroSciences LLC, a wholly-owned subsidiary of The Dow Chemical Company (NYSE: DOW), announced today that the companies have reached a non-exclusive global option and licensing agreement on Dow AgroSciences’ EXZACT™ Precision Technology® Platform for research and commercial development of new crop solutions across Monsanto Company’s research portfolio....

Read More

GENOME EDITING TECH PATENT APPLICATION ‘WITHDRAWN’: IP OFFICE

biotech | January 12, 2017

news image

China's intellectual property authority said it considers as withdrawn the genome editing technology patent application of researchers from Hebei University of Science and Technology (HUST) and Zhejiang University since they failed to reply to a notice on time. According to the State Intellectual Property Office, since researchers Han Chunyu and Shen Xiao did not reply, the patent application for the genome editing technology NgAgo is considered to have been withdrawn, thepaper.cn reported&n...

Read More

JOHNSON & JOHNSON INNOVATION, NEW YORK STATE AND NEW YORK GENOME CENTER COLLABORATE TO LAUNCH JLABS IN NEW YORK CITY

San Jose BioCenter | January 09, 2017

news image

Called JLABS @ NYC, 30,000-square foot facility will hold capacity for up to 30 life science startups focused on biotech, pharmaceutical, medical device and consumer health New collaboration receives $17 million in New York State funding and will support growth of healthcare solutions in the region by providing development...

Read More

IQ4I RESEARCH & CONSULTANCY PUBLISHED A NEW REPORT ON “GENOME EDITING GLOBAL MARKET – FORECAST TO 2022”

einnews | March 01, 2017

news image

Increased R&D expenditure and growth of biotechnology and pharmaceutical industries, increasing private and public sector funding, rapid advancements in sequencing and gene editing technologies, non-labeling of gene edited products as Genetically Modified Organisms (GMOs), applications in various drug discovery processes and are some of the factors driving the genome editing global market growth. Factors such as stringent regulatory framework, ethical issues concerning editing human embryo a...

Read More
news image

MONSANTO AND DOW AGROSCIENCES ANNOUNCE GLOBAL LICENSING AGREEMENT ON EXZACT PRECISION TECHNOLOGY GENOME-EDITING PLATFORM

Dow AgroSciences | October 03, 2016

Monsanto Company (NYSE: MON) and Dow AgroSciences LLC, a wholly-owned subsidiary of The Dow Chemical Company (NYSE: DOW), announced today that the companies have reached a non-exclusive global option and licensing agreement on Dow AgroSciences’ EXZACT™ Precision Technology® Platform for research and commercial development of new crop solutions across Monsanto Company’s research portfolio....

Read More
news image

GENOME EDITING TECH PATENT APPLICATION ‘WITHDRAWN’: IP OFFICE

biotech | January 12, 2017

China's intellectual property authority said it considers as withdrawn the genome editing technology patent application of researchers from Hebei University of Science and Technology (HUST) and Zhejiang University since they failed to reply to a notice on time. According to the State Intellectual Property Office, since researchers Han Chunyu and Shen Xiao did not reply, the patent application for the genome editing technology NgAgo is considered to have been withdrawn, thepaper.cn reported&n...

Read More
news image

JOHNSON & JOHNSON INNOVATION, NEW YORK STATE AND NEW YORK GENOME CENTER COLLABORATE TO LAUNCH JLABS IN NEW YORK CITY

San Jose BioCenter | January 09, 2017

Called JLABS @ NYC, 30,000-square foot facility will hold capacity for up to 30 life science startups focused on biotech, pharmaceutical, medical device and consumer health New collaboration receives $17 million in New York State funding and will support growth of healthcare solutions in the region by providing development...

Read More
news image

IQ4I RESEARCH & CONSULTANCY PUBLISHED A NEW REPORT ON “GENOME EDITING GLOBAL MARKET – FORECAST TO 2022”

einnews | March 01, 2017

Increased R&D expenditure and growth of biotechnology and pharmaceutical industries, increasing private and public sector funding, rapid advancements in sequencing and gene editing technologies, non-labeling of gene edited products as Genetically Modified Organisms (GMOs), applications in various drug discovery processes and are some of the factors driving the genome editing global market growth. Factors such as stringent regulatory framework, ethical issues concerning editing human embryo a...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us